CHEK2 and breast carcinoma: Germline pathogenic variants (PVs) in ATM, BRCA1, BRCA2, CHEK2, and PALB2 are detected in 5-7% of unselected women with breast cancer in the general population and are associated with a significantly increased risk of breast cancer in unaffected women [4,5].